Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:2.6.1.2 (alanine aminotransferase)
 26,722 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Viral hepatitis is still the most serious post-transfusion complication. Despite the routine screening of donor blood for the hepatitis type B surface antigen in the United States, post-transfusion hepatitis develops in approximately 7% of blood recipients. Type B hepatitis accounts for only 10% to 15% of cases; non-A, non-B hepatitis constitutes the remainder. Non-A, non-B hepatitis is usually asymptomatic and anicteric but often runs a prolonged course manifested by persistent or intermittent elevations of alanine aminotransferase levels. The risk of developing non-A, non-B hepatitis is increased considerably when blood from paid rather than volunteer donors is transfused. Although there are currently no definitive preventive measures that can be used to reduce the attack rate, the possibility of developing a serologic test fot the non-A, non-B agent is under active investigation.
 ...
PMID:Post-transfusion hepatitis: current perspectives. 698 32

The normal level of human serum alcohol dehydrogenase (EC 1.1.1.1) (ADH) activity which is not measurable by conventional methods was found to be within the range 0.07-0.56 U/1 when measured by a sensitive method based on a coenzyme recycling reaction. In different liver diseases the normal upper limit of serum ADH activity was found to be exceeded up to 70 times. Although ADH activity under pathological conditions usually parallels that of other enzymes, e.g., sorbitol dehydrogenase (EC 1.1.1.14) (SDH) and alanine transaminase (EC 2.6.1.2) (ALT), its relative elevation above the upper normal limit is generally greater, particularly in the early stages of viral hepatitis. Observations on some patients also suggested that very early stages of liver damage, caused by drugs or secondary malignancy, could be detected by increases of serum ADH activity when the activities of some other liver specific enzymes were still within their normal values. A pilot experiment on rats, intoxicated with carbon tetrachloride, showed that serum ADH activity could reflect acute liver parenchymal damage more sensitively than SDH and ALT activity.
 ...
PMID:Serum alcohol dehydrogenase activity in liver diseases. 703 78

Cobalt-activated acylase (Co-A) and transaminase activity were determined in the serum of A/Jax, DBA/2 and C3H mice several days after an intraperitoneal injection of 1,000 lethal doses of murine hepatitis virus type 3 (MHV3). A significant rise in the enzyme activity was observed 1 day after the injection, followed by a decrease on day 2. In the case of the genetically resistant A/Jax strain, the Co-A level regularly decreased to reach normal values on days 7-8. On the contrary, among the fully susceptible DBA/2 strain mice (all dead on day 5), a second rise in acylase (Co-A) level was observed on days 3 and 4, much higher than the day-1 values. Among the mice of C3H strain, which is recorded as 'semi-susceptible', some individuals behaved like the susceptible DBA/2. The comparison of serum acylase activity with other liver function tests showed a correlation between Co-A and transaminases (ALT and AST) with C3H and DBA/2 strains, but no correlation with A/JAX resistant strain. gamma-Glutamyltransferase was not detectable in the serum of different strains during the time of experimentations. Our results suggest that Co-A activity correlates with the clinical course, and that Co-A is a sensitive indicator enzyme in the early phase of viral hepatitis.
 ...
PMID:A genetic study of serum levels of cobalt-activated acylase among susceptible, resistant and semiresistant strains of mice with experimental viral hepatitis. 715 76

Over a period of three years all children with acute viral hepatitis (n = 167) were examined for the presence of the abnormal lipoprotein X(LPX). Positive results could be found in 96% of patients with hepatitis A and in 82% of hepatitis B. A good correlation of LPX was ascertained with cholesterol, triglycerides, phospholipids, bilirubin, gamma-glutamyl transferase, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase and immunoglobulin M. Control after 29 days in hepatitis A and 46 days in hepatitis B showed absence of LPX and normal pattern of lipoprotein-electrophoresis. Enzyme activities were slightly elevated, lipids and immunoglobulin M remained above upper normal range. In acute phase of viral hepatitis lipoprotein X is the most specific test in determining the presence of cholestasis, but in views on course of disease serum-lipids and immunoglobulin M have a similar sensitivity like enzyme patterns.
 ...
PMID:[Diagnosis of cholestasis in acute viral hepatitis in childhood (author's transl)]. 719 25

We determined the serum molybdenum concentration by neutron activation analysis in apparently healthy subjects and in patients with diseases of the liver and biliary system. The level was found to be markedly elevated in the initial phase of acute viral hepatitis (mean +/- S.D. 3.10 +/- 1.46 ng/ml vs. 0.55 +/- 0.21 in controls) and to return to normal during convalescence, in parallel with the liver function tests. The most significant correlations were found between the serum molybdenum concentration and the serum levels of GOT ( r = 0.710, p less than 0.001) and GPT (r = 0.683, p less than 0.001). Besides, the serum molybdenum level (mean +/- S.D.) was observed to be definitely increased in patients with HBsAg-positive chronic active hepatitis (0.97 +/- 0.49 ng/ml), HBsAg-positive liver cirrhosis (1.01 +/- 0.50), alcoholic liver disease (1.32 +/- 0.56), liver metastases (1.40 +/-0.39), gallstones (1.28 +/- 0.38), tumors of the gallbladder or extrahepatic bile ducts (1.64 +/- 0.44), and carcinoma of the head of the pancreas (1.61 +/- 0.91). Finally, the serum molybdenum level was found to be raised in two patients with primary biliary cirrhosis and in two out of four patients with drug-induced liver injury. The etiologic mechanism and the clinical importance of the observed abnormality remain to be established. Our study enlarges the existing information concerning the disorders of trace element metabolism in liver diseases.
 ...
PMID:Serum molybdenum in diseases of the liver and biliary system. 720 61

Seven patients are described in whom HBsAg persisted for 13 to 98 months after acute viral hepatitis B and then became nondetectable. All patients subsequently developed anti-HBs. During the period of HBs-antigenemia, liver biopsies in five patients showed persistent viral hepatitis. Retrospectively, impending negativity of HBsAg was predictable in five patients by a decrease in HBsAg titer, and in four patients by persistent normalization of serum alanine aminotransferase. Although delayed clearance of HBsAg in patients with chronic hepatitis B virus infection is uncommon, it appears to be predictable.
 ...
PMID:Delayed HBsAg clearance in chronic hepatitis B viral infection. 730 92

Differential diagnosis of acute viral hepatitis, persistent chronic hepatitis, aggressive chronic hepatitis, and post-necrotic cirrhosis can reasonably be achieved on the basis of three well-known liver-function tests: aspartate aminotransferase, alanine aminotransferase, and glutamate dehydrogenase. With use of principal-component analysis, these four liver diseases can be characterized by two criteria: a "cytolytic" criterion, correlated particularly with a membrane-permeability test--namely, alanine aminotransferase activity--and a "mitochondrial damage" criterion, which is associated with above-normal ornithine carbamyltransferase and glutamate dehydrogenase activities.
 ...
PMID:Multivariate analysis of an enzymic profile for the differential diagnosis of viral hepatitis. 743 42

A fundamental role is attributed to the pathological immune response in the development of chronic hepatitis B. By virtue of its non-specific immune modulatory effect, levamisole is capable of improving impaired T-cell function. Hence, studies with treated and control groups were performed in determine the effect of levamisole in acute viral hepatitis and chronic active hepatitis B. In acute hepatitis B, levamisole promoted the normalization of GPT, the elimination of HBsAg; this improvement was preceded by higher GPT values and increased titres of IgG, IgA, and of anti-HBcore. In chronic active hepatitis in the first few months of treatment a moderate increase of the GPT and HBsAg levels occurred, followed later by a decrease of these values. At the same time the phytohaemagglutinin reactivity of lymphocytes increased, and so did the ratio of circulating active T-cells.
 ...
PMID:Levamisole treatment of acute viral hepatitis and HBsAG-positive chronic active hepatitis. 745 30

Major advances have been made in the therapy of chronic viral hepatitis B during the past several years. This period has witnessed the publication of large, multicenter trials of recombinant interferon alfa for chronic hepatitis B in the United States and the completion of several similarly designed studies in North America, Europe and Asia. These studies have defined an initial response rate of approximately 40% to 50%. In contrast to the experience with chronic hepatitis C, loss of viral replication is generally sustained. Repeat courses of therapy are likely to result in the same type of response as that observed initially. Quantitative assessment of viral replication (HBV DNA, HBeAg) is important in predicting the likelihood of response and in monitoring patients during therapy. Perhaps the most compelling reason to treat chronic hepatitis B with interferon is the disappearance of circulating HBsAg in one third of responders with a further increase in frequency of this phenomenon as follow-up continues. Another important advantage to treatment is the striking degree of histologic improvement that is frequently observed years after a response has been achieved. Although a substantial number of patients do not respond to interferon, several promising agents that should allow for a greater degree of success, when used either alone or in combination with interferon, are under study. A short course of corticosteroids prior to interferon appears to improve response rates in patients who have low ALT levels at baseline and has been the preferred approach for these patients at our medical center. Progress is being made in the development of safer interferon regimens for patients with mild-to-moderate hepatic decompensation. Nonetheless, even patients with marginal synthetic function, as reflected by albumin levels within the low-normal range, appear to be at greater risk for complications during therapy and should preferably be referred for inclusion in research programs. Appropriate patient selection remains a critical step for maximizing the safety as well as efficacy of interferon treatment.
 ...
PMID:Therapy for hepatitis B virus infection. 752 74

Two hundred cases of various kinds of viral hepatitis and hepatocellular carcinoma were tested for serum anti-HCV. The positive rates of anti-HVC in patients with severe hepatitis and patients with cirrhosis were 42.86% and 46.15%, respectively. They were significantly higher than those in patients with other kinds of hepatitis (P < 0.05). The positive rate of anti-HCV was 67.5% in patients with posttransfusion hepatitis, 20.47% in healthy blood donors. In posttransfusion hepatitis B it was only 2.5%. Our results demonstrated that blood transfusion played an important role in transmitting HCV. Our findings also indicated that dual infection of HBV and HCV was important in the course of chronic hepatitis, cirrhosis and severe hepatitis. 50% of the anti-HCV positive patients with chronic hepatitis had slightly elevated serum alanine aminotransferase level. This showed that liver damage caused by HCV may be a chronic course.
 ...
PMID:[The anti-HCV assay in viral hepatitis and hepatoma and the relationship between HCV infection and blood transfusion]. 753 55


<< Previous 1 2 3 4 5 6 7 8 9 10